Bauer H W, Klasser M, von Hanstein K L, Rolinger H, Schladitz G, Henke H D, Gimbel W, Steinbach K
Hochwald-Kliniken, Klinik für Orthopädie und Sportmedizin, Weiskirchen, Germany.
Clin Rheumatol. 1999;18(1):4-9. doi: 10.1007/s100670050043.
In this multicentre (five centres in Germany), randomised, double-blind, comparative study, 150 patients with painful degenerative joint disease according to EULAR criteria received either oxaceprol (200 mg three times daily) or diclofenac (25 mg three times daily) for 20 days. Joint function, the primary variable, assessed according to Lequesne's indices, improved equally in both treatment groups to a clinically relevant degree. Joint mobility improved by approximately 60% in both groups. By the end of therapy in both groups, the period of pain-free walking time had more than doubled and subjectively evaluated pain perception (VAS) was reduced by almost 50% without any significant differences between the treatments. The incidence of adverse drug reactions was similar in both groups but oxaceprol induced milder symptoms. Oxaceprol is as effective and better tolerated than diclofenac in the treatment of osteoarthritis.
在这项多中心(德国的五个中心)、随机、双盲、对照研究中,150例根据欧洲抗风湿病联盟(EULAR)标准诊断为疼痛性退行性关节病的患者,接受奥沙普秦(每日三次,每次200毫克)或双氯芬酸(每日三次,每次25毫克)治疗20天。根据勒凯斯内指数评估的主要变量关节功能,在两个治疗组中均有同等程度的改善,达到临床相关水平。两组的关节活动度均提高了约60%。在两组治疗结束时,无痛步行时间均增加了一倍多,主观评估的疼痛感觉(视觉模拟评分法,VAS)降低了近50%,两种治疗之间无任何显著差异。两组药物不良反应的发生率相似,但奥沙普秦引起的症状较轻。在骨关节炎治疗中,奥沙普秦与双氯芬酸疗效相当,但耐受性更好。